Bayesian Capital Management’s Immunogen Inc IMGN Stock Holding History

Bayesian Capital Management’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-147,282	Closed	-$2.34M	–	1090
2023 Q3	$2.34M	Buy	147,282 +60,600	+70%	+$1.01M	0.27%	97
2023 Q2	$1.64M	Buy	+86,682	New	+$1.02M	0.18%	162
2021 Q2	–	Sell	-10,000	Closed	-$81K	–	698
2021 Q1	$81K	Buy	+10,000	New	+$81.7K	0.02%	500
2020 Q3	–	Sell	-12,400	Closed	-$57K	–	734
2020 Q2	$57K	Sell	12,400 -29,100	-70%	-$124K	0.01%	486
2020 Q1	$142K	Buy	+41,500	New	+$181K	0.03%	634
2019 Q2	–	Sell	-19,060	Closed	-$52K	–	709
2019 Q1	$52K	Buy	+19,060	New	+$82.6K	0.01%	518

Other funds holding IMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bayesian Capital Management's IMGN Position: Q4 2023 in Review

Bayesian Capital Management sold out of Immunogen Inc (IMGN) in Q4 2023, closing a stake of 147,282 shares — an estimated $2.34M sold.

Bayesian Capital Management first reported a position in IMGN in Q1 2019 and held it in 6 quarters. The position peaked at $2.34M in Q3 2023. 327 funds tracked by Wall St. Rank hold IMGN as of Q4 2023.

Bayesian Capital Management reported no remaining Immunogen Inc position as of Q4 2023 after selling out during the quarter.
Bayesian Capital Management sold 147,282 Immunogen Inc shares in Q4 2023, an estimated $2.34M.
Bayesian Capital Management first reported a position in Immunogen Inc in Q1 2019 and held it in 6 quarters.
Bayesian Capital Management's Immunogen Inc position peaked at $2.34M in Q3 2023.
327 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2023.

Based on Bayesian Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.